Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116817

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

N Pedersen, M Schmitt, E Rønne, M I Nicoletti, G Høyer-Hansen, M Conese, R Giavazzi, K Dano, W Kuhn, and F Jänicke

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Pedersen, N. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Schmitt, M. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Rønne, E. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Nicoletti, M. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Høyer-Hansen, G. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Conese, M. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Giavazzi, R. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Dano, K. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Kuhn, W. in: JCI | PubMed | Google Scholar

Institute of Microbiology, University of Copenhagen, Denmark.

Find articles by Jänicke, F. in: JCI | PubMed | Google Scholar

Published November 1, 1993 - More info

Published in Volume 92, Issue 5 on November 1, 1993
J Clin Invest. 1993;92(5):2160–2167. https://doi.org/10.1172/JCI116817.
© 1993 The American Society for Clinical Investigation
Published November 1, 1993 - Version history
View PDF
Abstract

We have identified a soluble form of the human urokinase plasminogen activator (uPA) receptor (uPAR) in the ascitic fluids from patients with ovarian cancer. After purification of uPAR from the ascitic fluids by ligand-affinity chromatography (pro-uPA Sepharose), the uPAR was initially identified by cross-linking to a radiolabeled amino-terminal fragment of human uPA. The uPAR purified from the ascitic fluid has no bound ligand (uPA), as similar amounts can be purified by ligand-affinity chromatography as by immuno-affinity chromatography. uPAR from ascitic fluids partitions in the water phase after a temperature-dependent phase separation of a detergent extract. It therefore lacks at least the lipid moiety of the glycophospholipid anchor present in cellular-bound uPARs. It is highly glycosylated and the deglycosylated form has the same electrophoretic mobility as previously characterized cellular uPAR from other sources. The immunoreactivity of the purified uPAR from the ascitic fluid is indistinguishable from that of characterized uPAR, demonstrated by Western blotting with three different anti-uPAR monoclonal antibodies. The uPAR was found in 11 of 11 ascitic fluids from patients with ovarian cancer and in elevated amounts in the plasma from 2 of 3 patients. The concentration of soluble uPAR in the ascitic fluid was estimated to range between 1 and 10 ng/ml. Human soluble uPAR, derived from the tumor cells, was also found in the ascitic fluid and serum from nude mice xenografted intraperitoneally with three different human ovarian carcinomas.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2160
page 2160
icon of scanned page 2161
page 2161
icon of scanned page 2162
page 2162
icon of scanned page 2163
page 2163
icon of scanned page 2164
page 2164
icon of scanned page 2165
page 2165
icon of scanned page 2166
page 2166
icon of scanned page 2167
page 2167
Version history
  • Version 1 (November 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts